Subcutaneous pertuzumab–trastuzumab: Efficiency, safety, and the biosimilar horizon
Aydin A.A.
Breast, 2026
RaporQ1Açık erişimSubcutaneous Drug Delivery Innovations in OncologyTargeted Antibody Therapies in Cancer Treatment
Doçent
İstinye Üniversitesi
Tıp Fakültesi
İç Hastalıkları Anabilim Dalı
Yayın Bul
Kayıt bulundu: 50
0 aktif filtre
Subcutaneous pertuzumab–trastuzumab: Efficiency, safety, and the biosimilar horizon
Aydin A.A.
Breast, 2026
Subcutaneous pertuzumab-trastuzumab: Efficiency, safety, and the biosimilar horizon
Aydin, AA
BREAST, 2026
Cabozantinib Beyond VEGFR Inhibition: Reprogramming the IO-Refractory Microenvironment in Metastatic RCC
Aydin, AA
CLINICAL GENITOURINARY CANCER, 2026
Cabozantinib Beyond VEGFR Inhibition: Reprogramming the IO-Refractory Microenvironment in Metastatic RCC
Aydin A.A.
Clinical Genitourinary Cancer, 2026
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights
Cetinkaya, AM
AMERICAN JOURNAL OF CANCER RESEARCH, 2026
Refining risk stratification in PSMA-PET guided salvage radiotherapy: methodological and translational considerations
Aydin, AA
RADIOTHERAPY AND ONCOLOGY, 2026
Beyond BMI: Metabolic and Inflammatory Determinants of Recurrence After Neoadjuvant Therapy in Breast Cancer
Aydin A.A.
Clinical Breast Cancer, 2026
Minimally Invasive Surgery Versus SABR in Stage IA NSCLC: Interpreting Real-World Evidence with Caution
Aydin A.A.
Clinical Lung Cancer, 2026
Re: Muhammet Demirbilek, Göktuğ Kalender, Said Bıyıkoglu, et al. External Validation of Nomograms for Predicting Pelvic Lymph Node Metastases in Patients with Prostate Cancer and the Added Value of the Prostate-specific Membrane Antigen Positron Emission Tomography–based PRIMARY Score. Eur Urol Open Sci 2025;82:170–7
Aydin A.A.
European Urology Open Science, 2026
Refining risk stratification in PSMA-PET guided salvage radiotherapy: methodological and translational considerations
Aydin A.A.
Radiotherapy and Oncology, 2026
Minimally Invasive Surgery Versus SABR in Stage IA NSCLC: Interpreting Real-World Evidence with Caution
Aydin, AA
CLINICAL LUNG CANCER, 2026
Beyond BMI: Metabolic and Inflammatory Determinants of Recurrence After Neoadjuvant Therapy in Breast Cancer
Aydin, AA
CLINICAL BREAST CANCER, 2026
Sayfa 1 / 5
